HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42,861 | +6.2% | 1,122 | +0.3% | 0.00% | – |
| Q2 2023 | $40,363 | +71.6% | 1,119 | +81.7% | 0.00% | – |
| Q1 2023 | $23,526 | -23.3% | 616 | +14.3% | 0.00% | – |
| Q4 2022 | $30,669 | +53.3% | 539 | +5.3% | 0.00% | – |
| Q3 2022 | $20,000 | -13.0% | 512 | -2.1% | 0.00% | – |
| Q2 2022 | $23,000 | +15.0% | 523 | +2.8% | 0.00% | – |
| Q1 2022 | $20,000 | 0.0% | 509 | +1.8% | 0.00% | – |
| Q4 2021 | $20,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2021 | $20,000 | -13.0% | 500 | 0.0% | 0.00% | – |
| Q2 2021 | $23,000 | +9.5% | 500 | 0.0% | 0.00% | – |
| Q1 2021 | $21,000 | 0.0% | 500 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $21,000 | +61.5% | 500 | 0.0% | 0.00% | – |
| Q3 2020 | $13,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2020 | $13,000 | +44.4% | 500 | 0.0% | 0.00% | – |
| Q1 2020 | $9,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2019 | $9,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |